In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, KalVista Pharmaceuticals Inc’s stock clocked out at $8.83, up 5.62% from its previous closing price of $8.36. In other words, the price has increased by $5.62 from its previous closing price. On the day, 0.85 million shares were traded. KALV stock price reached its highest trading level at $8.86 during the session, while it also had its lowest trading level at $8.15.
Ratios:
To gain a deeper understanding of KALV’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.87 and its Current Ratio is at 6.87. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on December 18, 2024, initiated with a Buy rating and assigned the stock a target price of $22.
On June 15, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On July 29, 2019, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $31.SVB Leerink initiated its Outperform rating on July 29, 2019, with a $31 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 09 ’24 when Palleiko Benjamin L sold 7,627 shares for $9.75 per share. The transaction valued at 74,363 led to the insider holds 274,596 shares of the business.
Audhya Paul K. sold 2,187 shares of KALV for $21,586 on Nov 26 ’24. The CHIEF MEDICAL OFFICER now owns 97,012 shares after completing the transaction at $9.87 per share. On Nov 26 ’24, another insider, Yea Christopher, who serves as the CHIEF DEVELOPMENT OFFICER of the company, sold 1,963 shares for $9.87 each. As a result, the insider received 19,378 and left with 91,142 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KALV now has a Market Capitalization of 436360928 and an Enterprise Value of 240798368.
Stock Price History:
Over the past 52 weeks, KALV has reached a high of $16.88, while it has fallen to a 52-week low of $7.97. The 50-Day Moving Average of the stock is -14.66%, while the 200-Day Moving Average is calculated to be -24.13%.
Shares Statistics:
It appears that KALV traded 397.93K shares on average per day over the past three months and 479360 shares per day over the past ten days. A total of 43.27M shares are outstanding, with a floating share count of 34.67M. Insiders hold about 29.84% of the company’s shares, while institutions hold 74.28% stake in the company. Shares short for KALV as of 1731628800 were 7370968 with a Short Ratio of 18.24, compared to 1728950400 on 6810297. Therefore, it implies a Short% of Shares Outstanding of 7370968 and a Short% of Float of 16.93.
